Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352391 | 0.82 | ALDH1A1 (0.74) | ALDH1A1CYP2C9TSHRGAAKDM4E | |
| SCHEMBL5344906 | 0.75 | ELANE (0.33) | ALDH1A1CYP2C9GAACYP1A2HIF1A | |
| SCHEMBL20253615 | 0.70 | ALDH1A1 (0.41) | ALDH1A1CYP2C9TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL25121396 | 0.68 | MAPK1 (0.60) | ALDH1A1CYP2C9TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL14968124 | 0.67 | ALDH1A1 (0.37) | ALDH1A1CYP2C9TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL14019723 | 0.65 | NPSR1 (0.35) | ALDH1A1CYP2C9TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL14967393 | 0.61 | POLB (0.35) | ALDH1A1SMN1; SMN2POLBCYP1A2HIF1A | |
| SCHEMBL20253723 | 0.60 | ALDH1A1 (0.33) | ALDH1A1CYP2C9TSHRMAPK1MAPT | |
| SCHEMBL21076349 | 0.60 | CYP2C9 (0.35) | ALDH1A1CYP2C9TSHRMAPK1SMN1; SMN2 | |
| SCHEMBL3400949 | 0.60 | SLC6A2 (0.40) | SMN1; SMN2CYP1A2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1132369-B1 | Malic acid and oxalacetic acid derivatives | DAICEL CHEM (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-6489504-B2 | Malic acid and oxalacetic acid derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20010056120-A1 | Malic acid and oxalacetic acid derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-1132369-A1 | Malic acid and oxalacetic acid derivatives | Daicel Chemical Industries, Ltd. (JP) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056120-A1 | Malic acid and oxalacetic acid derivatives | ME1, ME3, MLYCD | ALDH1A1 107/4885CYP2C9 541/4885TSHR 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.